Zusammenfassung
Die Einführung des Neugeborenenscreenings zur Früherkennung der angeborenen Hypothyreose führte zu neuen Erkenntnissen hinsichtlich Pathogenese, Diagnostik und Therapie des Krankheitsbilds. Die Mehrzahl (80%) der Patienten weisen Entwicklungsdefekte der Schilddrüse auf, nur 15–20% einen Biosynthesedefekt. Für beide Entitäten wurden molekulargenetische Ursachen nachgewiesen. Eine frühe, in den ersten beiden Lebenswochen mit ausreichender Dosis (10–15 µg/kg/Tag) L-Thyroxin initiierte Substitutionstherapie führt in über 90% der Fälle zu einer normalisierten Entwicklung. Bei sehr schweren Hypothyreosen, Defekten von Transkriptionsfaktoren, die auch in der Entwicklung des ZNS bedeutsam sind, und bei nicht ausreichender Compliance kann die Entwicklung trotz früher Diagnose beeinträchtigt sein. Derzeit ist nicht geklärt, ob eine persistierende Thyreotropinerhöhung bei normalen peripheren Schilddrüsenhormonspiegeln behandlungsbedürftig ist.
Abstract
The introduction of newborn screening programs has led to new concepts regarding the pathogenesis, diagnosis and therapy of congenital hypothyroidism. The majority (80%) of patients display developmental defects of the thyroid gland, and only 15%–20% have defective thyroid hormone biosynthesis. Molecular genetic studies have revealed heritable defects of candidate genes for both entities. Early and adequate treatment (10–15 mg/kg/day) with L-thyroxine has led to normal development in more than 90% of patients. Developmental deficits or neurological problems are observed in patients with very severe congenital hypothyroidism, defects of transcription factors also involved in CNS development and who comply poorly with treatment. To date it is unclear which patients with hyperthyrotropinemia and normal peripheral thyroid hormone concentrations will benefit from L-thyroxine therapy.
Literatur
Abramowicz MJ, Duprez L, Parma J et al. (1997) Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 99: 3018
Ambrugger P, Stoeva I, Biebermann H et al. (2001) Novel mutations of the thyroid peroxidase gene in patients with permanent congenital hypothyroidism. Eur J Endocrinol 145: 19–24
American Academy of Pediatrics (2006) Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 117: 2290–2303
Bongers Schokking JJ, De Muinck Keizer-Schrama SMPF (2005) Influence of timing and dose of thyroid hormone replacement on mental, psychomotor and behavioral development in children with congenital hypothyroidism. J Pediatr 147: 768–772
Brumm J, Pfeufer A, Biebermann H et al. (2002) Congenital central hypothyroidism due to a homozygous thyrotropin beta 313 delta T mutation is caused by a founder effect. J Clin Endocrinol Metab 87: 4811
Bundesausschuss der Ärzte und Krankenkassen (2005) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krankheiten bei Kindern bis zur Vollendung des 6. Lebensjahres (Kinder-Richtlinien) zur Einführung des erweiterten Neugeborenen-Screenings. BAnz 60: 4833
Calaciura F, Mendorla G, Distefano M et al. (1995) Childhood IQ measurements in infants with transient congenital hypothyroidism. Clin Endocrinol (Oxf) 43: 473–477
Dubuis JM, Glorieux J, Richer F et al. (1996) Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine treatment. J Clin Endocrinol Metab 81: 222–227
Fisher DA (1987) Effectiveness of newborn screening programs for congenital hypothyroidism: prevalence of missed cases. Pediatr Clin North Am 34: 881
Fisher DA, Schoen EJ, LaFranchi S et al. (2000) The hypothalamic-pituitary-thyroid negative feedback control axis in children with treated congenital hypothyroidism. J Clin Endocrinol Metab 85: 2722–2729
Grant DB (1994) Growth in early treated congenital hypothyroidism. Arch Dis Child 70: 464
Gruters A, Krude H, Biebermann H (2004) Molecular genetic defects in congenital hypothyroidism. Eur J Endocrinol 151: 39–44
Hishinuma A, Fukata S, Kakudo K et al. (2005) High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. Thyroid 15: 1079–1084
Kohler B, Schnabel D, Biebermann H et al. (1996) Transient congenital hypothyroidism and hyperthyrotropinemia: normal thyroid function and physical development at the ages of 6–14 years. J Clin Endocrinol Metab 81: 1563–1568
Krude H, Schütz B, Biebermann H et al. (2002) Choreoathetosis, hypothyroidism and pulmonary alterations due to human NKX2–1 haploinsufficiency. J Clin Invest 109: 475–480
LaFranchi SH, Hanna CE, Krainz PL et al. (1985) Screening for congenital hypothyroidism with specimen collection at two time periods results of the northwest regional screening program. Pediatrics 76: 734
Leger J, Marinovic D, Garel C et al. (2002) Thyroid developmental anomalies in first degree relatives of children with congenital hypothyroidism. J Clin Endocrinol Metab 87: 575
Moreno J, Klootwijk W, Van Toor H et al. (2008) Mutations in the iodotyrosine deiodinase gene and hypothyroidism. N Engl J Med 358: 1811–1818
Oerbeck B, K Sundet K, Kase B et al. (2005) Congenital hypothyroidism: no adverse effects of high dose thyroxine treatment on adult memory, attention and behaviour. Arch Dis Child 90: 132–137
Olivieri A, Stazi MA, Mastroiacovo P et al. (2002) A population based study on the frequency of additional congenital malformatons in infants with congenital hypothyroidism: data from the Italian registry for congenital hpothyroidism (1991–1998). J Clin Endocrinol Metab 87: 557–563
Pohlenz J, Refetoff S (1999) Mutations in the sodium/iodide symporter gene as a cause for iodide transport defects and congenital hypothyroidism. Biochemie 81: 469
Selva K, Harper A, Downs A et al. (2005) Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. J Pediatr 147: 775–782
Tonacchera M, Perri A, DeMarco G et al. (2004) Low prevalence of thyrotropin receptor mutations in a large series of subjects with sporadic and familial nonautoimmune subclinical hypothyroidism. J Clin Endocrinol Metab 89: 5787–5792
Tylek-Lemanska D, Kumorowicz-Kopiec M, Starzyk J (2005) Screening for congenital hypothyroidism: the value of retesting after four months in neonates with low or very low birth weight. J Med Screen 12: 166–169
Van der Sluijs Veer L, Kempers M, Last BF et al.T (2008) Quality of life, developmental milestones and self-esteem of young adults with congenital hypothyroidism diagnosed by neonatal screening. J Clin Endocrinol Metab 93: 2654–2661
Van Tijn DA, De Vijlder JJM, Verbeeten B jr et al. (2005) Neonatal detection of congenital hypothyroidism of central origin. J Clin Endocrinol Metab 90: 3350–3354
Van Trotsenburg ASP, Vulsma T, Van Rozenburg-Marres SL et al. (2005) The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab 90: 3304–3311
Van Wassenaer AG, Kok JH, Dekker FW et al. (1997) Thyroid function in very preterm infants influences of gestational age and disease. Pediatr Res 42: 604–609
Vigone MC, Fugazzola L, Zamproni I et al. (2005) Persistent mild hypothyroidism associated with novel sequence variants of the DUOX2 gene in two siblings. Hum Mutat 26: 395
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grüters, A., Krude, H. Angeborene Hypothyreose. Monatsschr Kinderheilkd 156, 951–960 (2008). https://doi.org/10.1007/s00112-008-1738-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00112-008-1738-3
Schlüsselwörter
- Angeborene Hypothyreose
- Neugeborenenscreening
- Entwicklungsdefekte der Schilddrüse
- Biosynthesedefekt
- Substitutionstherapie